GlassScriptPhysician profile
David H Lau
NPI 1902064421
$201,831.28
in general payments reported to CMS, 2019-2025
35 companies · $3,416 in 2025
The $3,416 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $6,003 · 2021: $56K · 2022: $46K · 2023: $22K · 2024: $6,781 · 2025: $3,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $12K · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,900.00 |
| Food and Beverage | $11,774.94 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $145,954.24 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $34,896.15 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $4,752.93 | 2019-2025 | General - Therapies, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Pfizer INC. | $2,959.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,874.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,573.53 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $1,224.71 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $1,029.00 | 2020-2023 | |
| Esperion Therapeutics, INC. | $900.01 | 2021-2023 | Nexletol |
| Abbott Laboratories | $882.83 | 2019-2025 | Aveir |
| Amgen INC. | $679.06 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $662.21 | 2022-2024 | Biomonitor, Acticor 7 Vr-T Dx, Pamira |
| Sanofi-Aventis U.S. LLC | $620.22 | 2020-2024 | |
| Celgene Corporation | $600.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $590.47 | 2021-2025 | Farxiga |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $388.16 | 2021-2022 | |
| Medtronic Vascular, INC. | $358.00 | 2019 | |
| Novo Nordisk INC | $262.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lexicon Pharmaceuticals, INC. | $255.59 | 2023-2024 | Inpefa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.62 | 2021-2022 | |
| Cleerly, INC. | $188.18 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $172.63 | 2022-2023 | |
| Heartflow, INC. | $144.94 | 2023 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $127.14 | 2019 | |
| Scpharmaceuticals INC. | $101.96 | 2023-2025 | |
| Astellas Pharma US INC | $89.99 | 2019 | |
| Lilly USA, LLC | $64.97 | 2023-2024 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $54.51 | 2023-2025 | Tirosint, Licart, Tirosint |
| Kowa Pharmaceuticals America, INC. | $45.68 | 2020-2023 | Livalo |
| Bard Peripheral Vascular, INC. | $32.95 | 2025 | Venclose Maven Catheter |
| Azurity Pharmaceuticals, INC. | $30.36 | 2023 | Edarbi |
| Agepha Pharma Fz LLC | $22.35 | 2025 | Lodoco |
| Kiniksa Pharmaceuticals International, Plc | $21.42 | 2024 | Arcalyst |
| Abbvie INC. | $13.59 | 2024 | |
| Arbor Pharmaceuticals, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.